Clinical and epidemiological features of ulcerative colitis patients in Sardinia, Italy: Results from a multicenter study

Table 1 Clinical and demographical characteristics of patients with ulcerative colitis

Characteristics	n = 442, n (%)
Female, n (%)	231 (52)
Age at diagnosis, yr (IQR)	39 (28-48)
Smoking status
Active	48 (10.9)
Former	160 (36.2)
Never	234 (52.9)
Disease extent at diagnosis
E1, proctitis	81 (18.3)
E2, left-sided colitis	178 (40.3)
E3, extensive colitis	176 (39.8)
Uncertain extent	7 (1.6)
Disease extent	53 (12)
E1 to E2	13 (25)
E2 to E3	28 (52.3)
E1 to E3	12 (22.7)
Extraintestinal manifestations	75 (16)
Articular	50 (69.4)
Hepatobiliary	11 (15.2)
Cutaneous	9 (12.5)
Ocular	5 (6.9)
Previous surgery	15 (3.4)
Colectomy	13 (87)
Hemicolectomy	2 (13)
Malignancies	19 (4)
Colorectal cancer	2 (11)
Breast	5 (26)
Skin	4 (21)
Prostate	2 (11)
Thyroid	2 (11)
Pancreas	1 (5)
Stomach	1 (5)
Multiple myeloma	1 (5)
MALT lymphoma	1 (5)
Self-reported vaccination status
HBV	134 (30.3)
HPV	9 (2)
Streptococcus pneumoniae	7 (1.6)

HBV: Hepatitis B virus; HPV: Human papilloma virus.

Table 2 Medical treatment in patients with ulcerative colitis

Medical therapy	Current users, n (%)	Former users, n (%)	Never used, n (%)
Mesalazine, n = 425	368 (86.6)	46 (10.8)	11 (2.6)
Corticosteroids	41 (9.1)	228 (51.7)	173 (39.2)
Thiopurines	40 (9)	69 (15.6)	333 (75.4)
Methotrexate	5 (1.1)	4 (1)	432 (97.9)
Infliximab	55 (12.4)	22 (5.0)	365 (82.6)
Adalimumab	12 (2.7)	6 (1.4)	424 (95.9)
Golimumab	5 (1.1)	11 (2.5)	426 (96.4)
Vedolizumab	11 (2.5)	1 (0.2)	430 (97.3)